Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neuroendocrine Tumors 3 Meningioma 3 Prostatic Neoplasms 2 Gastro-enteropancreatic neuroendocrine tumor 2 Neuroblastoma 1 Neoplasms 1 Glioma 1 Ganglioneuroma 1 Ganglioneuroblastoma 1 Disease 1 Carcinoid Tumor 1 Breast Neoplasms 1 Breast Cancer Metastatic 1 Advanced Gastroenteropancreatic Neuroendocrine Tumor 1

Interventions

Fulvestrant 6 Letrozole 4 exemestane 3 dalpiciclib 3 Trastuzumab 3 Docetaxel 3 Capecitabine 3 Anastrozole 3 ribociclib 2 palbociclib 2 fluzoparib 2 apatinib 2 Irinotecan 2 Gemcitabine 2 tusamitamab ravtansine 1 trastuzumab deruxtecan 1 sacituzumab govitecan 1 pyrotinib 1 pegfilgrastim 1 patritumab deruxtecan 1 olaparib 1 nirogacestat 1 margetuximab 1 irinotecan sucrosofate 1 abemaciclib 1 Zoledronic Acid 1 Vinorelbine 1 Tamoxifen 1 Rogaratinib 1 Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Breast Cancer Metastatic × Ga(III)-DOTATOC × Clear all

NCT06611891 2025-03-04

DOTABREAST

University Hospital, Grenoble

Phase 3 Recruiting

Breast Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡